Immunotherapy for the treatment of breast cancer (Q38353772)

2 September 2017

1 reference

title

Immunotherapy for the treatment of breast cancer. (English)

1 reference

2 September 2017

1 reference

Brenda Ernst

1

1 reference

2 September 2017

Karen S Anderson

series ordinal

2

1 reference

2 September 2017

language of work or name

1 reference

1 February 2015

1 reference

2 September 2017

published in

Current Oncology Reports

1 reference

2 September 2017

volume

17

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

5

1 reference

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Cytokines in the management of high risk or advanced breast cancer: an update and expectation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Role of interleukin-10 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Myeloid-derived suppressor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Agonist antibodies to TNFR molecules that costimulate T and NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Advances in targeting cell surface signalling molecules for immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

mTOR regulates memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Rapamycin: could it enhance vaccine efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Triple-negative breast cancer: molecular subtypes and targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

The GP2 peptide: a HER2/neu-based breast cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

AE37: a novel T-cell-eliciting vaccine for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Emerging immunotherapy strategies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Carcinoembryonic antigen gene family: molecular biology and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Study of circulating antibodies against CD25 and FOXP3 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Tumor vaccines for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-014-0426-9

Immunotherapy strategies in the treatment of breast cancer

21 January 2018

1 reference

12 December 2020

Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention

1 reference

12 December 2020

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

1 reference

12 December 2020

Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine

1 reference

12 December 2020

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

1 reference

12 December 2020

mTOR inhibitors in the treatment of breast cancer

1 reference

12 December 2020

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy

1 reference

12 December 2020

A tumor suppressor and oncogene: the WT1 story.

1 reference

12 December 2020

NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration

1 reference

12 December 2020

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

1 reference

12 December 2020

Therapeutic vaccines for cancer: an overview of clinical trials

1 reference

12 December 2020

10.1007/S11912-014-0426-9

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1047402059

0 references

1 reference